L-DOS 47

Drug Profile

L-DOS 47

Alternative Names: L-DOS-47

Latest Information Update: 20 Dec 2016

Price : $50

At a glance

  • Originator Helix BioPharma
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Ureases
  • Mechanism of Action Urease stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 07 Dec 2016 Efficacy, adverse event and immunogenicity data from a phase I/II trial in Non-small cell lung cancer presented at the 17th World Conference on Lung Cancer (WCLC-2016)
  • 28 Apr 2016 Phase-II clinical trials in Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease, Monotherapy) in Poland (IV) (9195069; 9199713)
  • 21 Jan 2016 Helix BioPharma initiates enrolment in the phase I LDOS001 trial for Non-small cell lung cancer (Combination therapy, Metastatic disease, Recurrent, Late-stage disease) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top